JAZZ PHARMACEUTICALS PLC (JAZZ) Fundamental Analysis & Valuation

NASDAQ:JAZZ • IE00B4Q5ZN47

Current stock price

186.425 USD
-0.52 (-0.28%)
Last:

This JAZZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. JAZZ Profitability Analysis

1.1 Basic Checks

  • In the past year JAZZ was profitable.
  • In the past year JAZZ had a positive cash flow from operations.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • Each year in the past 5 years JAZZ had a positive operating cash flow.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • The Return On Assets of JAZZ (-3.05%) is better than 73.96% of its industry peers.
  • JAZZ's Return On Equity of -8.25% is fine compared to the rest of the industry. JAZZ outperforms 76.56% of its industry peers.
  • With an excellent Return On Invested Capital value of 4.34%, JAZZ belongs to the best of the industry, outperforming 81.77% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA -3.05%
ROE -8.25%
ROIC 4.34%
ROA(3y)1.75%
ROA(5y)0.1%
ROE(3y)5.51%
ROE(5y)0.19%
ROIC(3y)5%
ROIC(5y)3.72%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15 20

1.3 Margins

  • JAZZ's Operating Margin of 12.13% is amongst the best of the industry. JAZZ outperforms 83.33% of its industry peers.
  • JAZZ's Operating Margin has declined in the last couple of years.
  • JAZZ has a Gross Margin of 88.21%. This is amongst the best in the industry. JAZZ outperforms 90.63% of its industry peers.
  • JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.13%
PM (TTM) N/A
GM 88.21%
OM growth 3Y59.74%
OM growth 5Y-11.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y-1.2%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. JAZZ Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
  • The number of shares outstanding for JAZZ has been increased compared to 1 year ago.
  • The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
  • JAZZ has a better debt/assets ratio than last year.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.73, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.73 is in line compared to the rest of the industry. JAZZ outperforms 59.90% of its industry peers.
  • JAZZ has a debt to FCF ratio of 4.68. This is a neutral value as JAZZ would need 4.68 years to pay back of all of its debts.
  • The Debt to FCF ratio of JAZZ (4.68) is better than 83.85% of its industry peers.
  • A Debt/Equity ratio of 1.00 is on the high side and indicates that JAZZ has dependencies on debt financing.
  • JAZZ has a Debt to Equity ratio of 1.00. This is in the lower half of the industry: JAZZ underperforms 72.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 4.68
Altman-Z 1.73
ROIC/WACC0.61
WACC7.13%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.3 Liquidity

  • JAZZ has a Current Ratio of 1.86. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • JAZZ has a Current ratio of 1.86. This is in the lower half of the industry: JAZZ underperforms 64.58% of its industry peers.
  • JAZZ has a Quick Ratio of 1.67. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of JAZZ (1.67) is worse than 60.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.67
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. JAZZ Growth Analysis

3.1 Past

  • The earnings per share for JAZZ have decreased strongly by -61.30% in the last year.
  • Measured over the past years, JAZZ shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.04% on average per year.
  • Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.88% in the last year.
  • Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 12.54% on average per year.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y5.26%
Revenue growth 5Y12.54%
Sales Q2Q%10.09%

3.2 Future

  • JAZZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.81% yearly.
  • The Revenue is expected to grow by 7.16% on average over the next years.
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue Next Year4.77%
Revenue Next 2Y6.25%
Revenue Next 3Y6.95%
Revenue Next 5Y7.16%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. JAZZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 22.73, which indicates a rather expensive current valuation of JAZZ.
  • JAZZ's Price/Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 80.73% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.17. JAZZ is around the same levels.
  • With a Price/Forward Earnings ratio of 7.48, the valuation of JAZZ can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
  • JAZZ is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.73
Fwd PE 7.48
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 85.94% of the companies listed in the same industry.
  • 90.10% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.01
EV/EBITDA 11.02
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

  • JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • JAZZ's earnings are expected to grow with 49.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y75.53%
EPS Next 3Y49.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAZZ Dividend Analysis

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ Fundamentals: All Metrics, Ratios and Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (4/6/2026, 10:43:04 AM)

186.425

-0.52 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners102.46%
Inst Owner Change0%
Ins Owners2.49%
Ins Owner Change2.04%
Market Cap11.48B
Revenue(TTM)4.27B
Net Income(TTM)-356.15M
Analysts85.22
Price Target228.13 (22.37%)
Short Float %10.36%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.27%
Min EPS beat(2)-0.11%
Max EPS beat(2)34.65%
EPS beat(4)1
Avg EPS beat(4)-9.11%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-4.44%
EPS beat(12)4
Avg EPS beat(12)-4.44%
EPS beat(16)6
Avg EPS beat(16)-10.63%
Revenue beat(2)1
Avg Revenue beat(2)0.16%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)0.75%
Revenue beat(4)1
Avg Revenue beat(4)-3.11%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.75%
Revenue beat(8)2
Avg Revenue beat(8)-2.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.02%
Revenue beat(16)3
Avg Revenue beat(16)-2.1%
PT rev (1m)1.94%
PT rev (3m)4.82%
EPS NQ rev (1m)-6.57%
EPS NQ rev (3m)-3.5%
EPS NY rev (1m)0%
EPS NY rev (3m)8.26%
Revenue NQ rev (1m)-1.51%
Revenue NQ rev (3m)-0.72%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-1.37%
Valuation
Industry RankSector Rank
PE 22.73
Fwd PE 7.48
P/S 2.69
P/FCF 10.01
P/OCF 8.46
P/B 2.66
P/tB N/A
EV/EBITDA 11.02
EPS(TTM)8.2
EY4.4%
EPS(NY)24.93
Fwd EY13.37%
FCF(TTM)18.62
FCFY9.99%
OCF(TTM)22.02
OCFY11.81%
SpS69.32
BVpS70.15
TBVpS-31.52
PEG (NY)0.11
PEG (5Y)N/A
Graham Number113.77
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -8.25%
ROCE 5.5%
ROIC 4.34%
ROICexc 5.86%
ROICexgc 57.11%
OM 12.13%
PM (TTM) N/A
GM 88.21%
FCFM 26.85%
ROA(3y)1.75%
ROA(5y)0.1%
ROE(3y)5.51%
ROE(5y)0.19%
ROIC(3y)5%
ROIC(5y)3.72%
ROICexc(3y)6.52%
ROICexc(5y)4.68%
ROICexgc(3y)48.58%
ROICexgc(5y)33.56%
ROCE(3y)6.33%
ROCE(5y)4.72%
ROICexgc growth 3Y116.75%
ROICexgc growth 5Y-3.48%
ROICexc growth 3Y83.19%
ROICexc growth 5Y-11.56%
OM growth 3Y59.74%
OM growth 5Y-11.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y-1.2%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 4.68
Debt/EBITDA 3.57
Cap/Depr 30.12%
Cap/Sales 4.92%
Interest Coverage 2.08
Cash Conversion 111.69%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.67
Altman-Z 1.73
F-Score5
WACC7.13%
ROIC/WACC0.61
Cap/Depr(3y)14.71%
Cap/Depr(5y)26.3%
Cap/Sales(3y)2.41%
Cap/Sales(5y)4.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y5.26%
Revenue growth 5Y12.54%
Sales Q2Q%10.09%
Revenue Next Year4.77%
Revenue Next 2Y6.25%
Revenue Next 3Y6.95%
Revenue Next 5Y7.16%
EBIT growth 1Y-29.56%
EBIT growth 3Y68.14%
EBIT growth 5Y0.13%
EBIT Next Year224.91%
EBIT Next 3Y53.46%
EBIT Next 5Y32.4%
FCF growth 1Y-14.97%
FCF growth 3Y13.99%
FCF growth 5Y17.11%
OCF growth 1Y-2.88%
OCF growth 3Y2.15%
OCF growth 5Y8.55%

JAZZ PHARMACEUTICALS PLC / JAZZ Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


What is the profitability of JAZZ stock?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 5 / 10.


What is the valuation of JAZZ PHARMACEUTICALS PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 22.73 and the Price/Book (PB) ratio is 2.66.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 204.02% in the next year.